Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Bang For Celgene’s Buck: Looking Inside The Record-Setting Juno Deal

Executive Summary

Celgene’s $1 billion collaboration with Juno was the highest ever upfront payment for a biopharma licensing deal. Execs broke down the deal specifics in an interview with “The Pink Sheet.”

You may also be interested in...



Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal

Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.

Bristol Goes In Big On New Valentine Nektar

Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.

Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T

Data from a Phase I trial testing the CAR-T therapy bb2121 in in heavily treated patients with relapsed refractory multiple myeloma were encouraging, driving bluebird's stock up 10%.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel